- Home
- LEGT vs XFOR Comparison
LEGT vs XFOR Comparison
Compare LEGT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGT
- XFOR
- Stock Information
- Founded
- LEGT 2023
- XFOR 2014
- Country
- LEGT United States
- XFOR United States
- Employees
- LEGT N/A
- XFOR N/A
- Industry
- LEGT
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEGT
- XFOR Health Care
- Exchange
- LEGT Nasdaq
- XFOR Nasdaq
- Market Cap
- LEGT 278.6M
- XFOR 332.3M
- IPO Year
- LEGT 2024
- XFOR N/A
- Fundamental
- Price
- LEGT $10.81
- XFOR $3.70
- Analyst Decision
- LEGT
- XFOR Strong Buy
- Analyst Count
- LEGT 0
- XFOR 3
- Target Price
- LEGT N/A
- XFOR $34.67
- AVG Volume (30 Days)
- LEGT 172.9K
- XFOR 604.7K
- Earning Date
- LEGT 01-01-0001
- XFOR 11-05-2025
- Dividend Yield
- LEGT N/A
- XFOR N/A
- EPS Growth
- LEGT N/A
- XFOR N/A
- EPS
- LEGT 0.33
- XFOR N/A
- Revenue
- LEGT N/A
- XFOR $33,979,000.00
- Revenue This Year
- LEGT N/A
- XFOR $1,307.51
- Revenue Next Year
- LEGT N/A
- XFOR N/A
- P/E Ratio
- LEGT $32.88
- XFOR N/A
- Revenue Growth
- LEGT N/A
- XFOR 2925.74
- 52 Week Low
- LEGT $10.28
- XFOR $1.35
- 52 Week High
- LEGT $11.25
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- LEGT 44.49
- XFOR 51.95
- Support Level
- LEGT $10.79
- XFOR $3.49
- Resistance Level
- LEGT $10.84
- XFOR $3.90
- Average True Range (ATR)
- LEGT 0.06
- XFOR 0.23
- MACD
- LEGT -0.02
- XFOR -0.01
- Stochastic Oscillator
- LEGT 4.35
- XFOR 67.19
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.